ArticleBMC complementary medicine and therapies2026
Exploration of borneol essential oil function in the treatment of Alzheimer's disease based on network pharmacology and experimental validation.
Article in BMC complementary medicine and therapies, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundBorneol essential oil was obtained by distillation with steam from the branches and leaves of Cinnamomum camphora chvar. Borneol alleviates learning and memory impairments, but it is not known whether and how it exerts an effect on Alzheimer’s Disease (AD). To explore the possible mechanisms of borneol essential oil in AD via network pharmacology and molecular docking.
methodsGas chromatography–time-of-flight mass spectrometry (GC-TOFMS) was used to characterize the volatile constituents of borneol essential oil, followed by network pharmacology analysis to elucidate the core targets and key signaling pathways underlying its potential therapeutic effects on Alzheimer’s disease. Molecular docking was used to find out the active components of the essential oil of borneol. Behavioral tests, enzyme-linked immunosorbent assay (ELISA), western blotting (WB), and immunohistochemistry (IHC) were run in an amyloid precursor protein/presenilin 1 (APP/PS1) transgenic mouse AD model. The impact of borneol essential oil on improving AD symptoms and its mechanisms, mainly focusing on the anti-inflammatory ones, was explored.
resultsFive core targets of the essential oil—ESR1, MAPK3, PGR, ERBB2, and MAPK1—were treated with AD. The NF-κB pathway was the main signaling pathway and guaiol was the main active ingredient. And also borneol essential oil alleviated the cognitive deficit, motor deficit, and pathological phenomena in APP/PS1 model mice. Mechanically, they were correlated with downregulation of the extracellular signal-regulated kinase (ERK)/nuclear factor kappa B (NF-κB) signaling pathway, suggesting anti-inflammatory effects that may contribute to the modulation of AD-related pathology.
conclusionBorneol essential oil alleviated neuroinflammatory responses and ameliorated AD-like pathological features in APP/PS1 mice through modulation of the ERK/NF-κB pathway.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.